CA2692506C - Pyrimidyl cyclopentanes as akt protein kinase inhibitors - Google Patents

Pyrimidyl cyclopentanes as akt protein kinase inhibitors Download PDF

Info

Publication number
CA2692506C
CA2692506C CA2692506A CA2692506A CA2692506C CA 2692506 C CA2692506 C CA 2692506C CA 2692506 A CA2692506 A CA 2692506A CA 2692506 A CA2692506 A CA 2692506A CA 2692506 C CA2692506 C CA 2692506C
Authority
CA
Canada
Prior art keywords
compound
alkyl
formula
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2692506A
Other languages
English (en)
French (fr)
Other versions
CA2692506A1 (en
Inventor
Josef R. Bencsik
James F. Blake
Nicholas C. Kallan
Ian S. Mitchell
Keith L. Spencer
Dengming Xiao
Rui Xu
Christine Chabot
Jun Liang
Brian S. Safina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2692506A1 publication Critical patent/CA2692506A1/en
Application granted granted Critical
Publication of CA2692506C publication Critical patent/CA2692506C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2692506A 2007-07-05 2008-07-03 Pyrimidyl cyclopentanes as akt protein kinase inhibitors Expired - Fee Related CA2692506C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94814707P 2007-07-05 2007-07-05
US60/948,147 2007-07-05
PCT/US2008/069147 WO2009006569A1 (en) 2007-07-05 2008-07-03 Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CA2692506A1 CA2692506A1 (en) 2009-01-08
CA2692506C true CA2692506C (en) 2015-11-24

Family

ID=39830222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692506A Expired - Fee Related CA2692506C (en) 2007-07-05 2008-07-03 Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Country Status (15)

Country Link
US (1) US8377937B2 (enExample)
EP (2) EP2173723B3 (enExample)
JP (2) JP5542282B2 (enExample)
KR (2) KR20150091196A (enExample)
CN (1) CN101918373B (enExample)
AT (1) ATE522509T1 (enExample)
AU (1) AU2008272832B2 (enExample)
BR (1) BRPI0813993A2 (enExample)
CA (1) CA2692506C (enExample)
ES (1) ES2533557T3 (enExample)
IL (1) IL202617A0 (enExample)
MX (1) MX2009014013A (enExample)
SI (1) SI2173723T1 (enExample)
WO (1) WO2009006569A1 (enExample)
ZA (1) ZA200908901B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) * 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
MX2010007546A (es) 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
CA2711782C (en) 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
GB201110546D0 (en) * 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
DK2861583T3 (en) * 2012-05-17 2016-10-03 Array Biopharma Inc METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP2019537585A (ja) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Ｅｚｈ２媒介性がんを治療するための組成物および方法
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
JP2021527666A (ja) 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
KR20220154722A (ko) * 2020-03-17 2022-11-22 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
TW202328138A (zh) * 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
CN116514739B (zh) * 2023-05-09 2025-07-22 天津绿菱气体股份有限公司 一种1,4-二甲基哌嗪及其制备方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885035A (en) 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) * 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
JPS562968A (en) 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
US4749704A (en) 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
PT664291E (pt) 1992-10-05 2000-11-30 Ube Industries Composto de pirimidina
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
ES2356886T3 (es) * 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1140062B1 (en) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
IL144103A0 (en) 1999-01-07 2002-05-23 Warner Lambert Co Antiviral method using mek inhibitors
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
AU2482700A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 1-heterocycle substituted diarylamines
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
JP2002534497A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CN1365277A (zh) 1999-07-16 2002-08-21 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
KR20020015379A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 엠이케이 억제제를 사용하는 만성 동통의 치료방법
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
JP2004507518A (ja) 2000-08-25 2004-03-11 ワーナー−ランバート・カンパニー・エルエルシー Ｎ−アリール−アントラニル酸及びその誘導体の製造法
DK1318997T3 (da) * 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc HEMMER OF ACT ACTIVITY
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
AU2003230367A1 (en) 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
CA2501365C (en) 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20050045867A1 (en) * 2002-10-30 2005-03-03 Ozkan Cengiz S. Nanoscale heterojunctions and methods of making and using thereof
EP1428793B1 (en) * 2002-12-12 2011-02-09 Sony Deutschland GmbH Soluble carbon nanotubes
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
AR045445A1 (es) 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
CA2534785A1 (en) 2003-08-12 2005-02-17 Robin Douglas Clark Tetrahydroquinazoline derivatives as cfr antagonists
US20070027156A1 (en) 2003-09-09 2007-02-01 Hisao Nakai Crf antagonists and heterobicyclic compounds
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
US7556746B2 (en) * 2004-06-03 2009-07-07 Nantero, Inc. Method of making an applicator liquid for electronics fabrication process
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
AR056691A1 (es) 2005-10-13 2007-10-17 Glaxo Group Ltd Derivados pirrolopirimidina como inhibidores de syk
CA2635541A1 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
MX2009014013A (es) 2010-01-28
EP2404907B1 (en) 2015-01-14
IL202617A0 (en) 2010-06-30
SI2173723T1 (sl) 2011-12-30
KR101624361B1 (ko) 2016-05-25
JP5542282B2 (ja) 2014-07-09
AU2008272832A1 (en) 2009-01-08
EP2173723B3 (en) 2014-11-19
ZA200908901B (en) 2011-10-26
CN101918373A (zh) 2010-12-15
CN101918373B (zh) 2013-06-05
HK1166078A1 (en) 2012-10-19
HK1136832A1 (en) 2010-07-09
AU2008272832B2 (en) 2014-02-20
EP2404907A1 (en) 2012-01-11
RU2010103811A (ru) 2011-08-10
WO2009006569A1 (en) 2009-01-08
KR20150091196A (ko) 2015-08-07
BRPI0813993A2 (pt) 2015-06-16
JP2014040489A (ja) 2014-03-06
KR20100029846A (ko) 2010-03-17
CA2692506A1 (en) 2009-01-08
EP2173723A1 (en) 2010-04-14
US8377937B2 (en) 2013-02-19
JP2010532387A (ja) 2010-10-07
US20110160221A1 (en) 2011-06-30
EP2173723B1 (en) 2011-08-31
ES2533557T3 (es) 2015-04-13
ATE522509T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
CA2692506C (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8618097B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR101578877B1 (ko) ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
US8846683B2 (en) Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2486178C2 (ru) Пиримидилциклопентаны в качестве ингибиторов akt-протеинкиназы
HK1166078B (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1136832B (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130702

MKLA Lapsed

Effective date: 20210705